394 related articles for article (PubMed ID: 29616397)
21. Activation of brain glucose metabolism ameliorating cognitive impairment in APP/PS1 transgenic mice by electroacupuncture.
Liu W; Zhuo P; Li L; Jin H; Lin B; Zhang Y; Liang S; Wu J; Huang J; Wang Z; Lin R; Chen L; Tao J
Free Radic Biol Med; 2017 Nov; 112():174-190. PubMed ID: 28756309
[TBL] [Abstract][Full Text] [Related]
22. Treadmill exercise enhances synaptic plasticity, but does not alter β-amyloid deposition in hippocampi of aged APP/PS1 transgenic mice.
Zhao G; Liu HL; Zhang H; Tong XJ
Neuroscience; 2015 Jul; 298():357-66. PubMed ID: 25917310
[TBL] [Abstract][Full Text] [Related]
23. A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice.
Wang ZJ; Han YF; Zhao F; Yang GZ; Yuan L; Cai HY; Yang JT; Holscher C; Qi JS; Wu MN
Horm Behav; 2020 Feb; 118():104640. PubMed ID: 31765661
[TBL] [Abstract][Full Text] [Related]
24. Xanthoceraside modulates NR2B-containing NMDA receptors at synapses and rescues learning-memory deficits in APP/PS1 transgenic mice.
Zhu L; Yang L; Zhao X; Liu D; Guo X; Liu P; Chi T; Ji X; Zou L
Psychopharmacology (Berl); 2018 Jan; 235(1):337-349. PubMed ID: 29124300
[TBL] [Abstract][Full Text] [Related]
25. DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP/PS1 transgenic mice.
Yang RY; Zhao G; Wang DM; Pang XC; Wang SB; Fang JS; Li C; Liu AL; Wu S; Du GH
Pharmacol Biochem Behav; 2015 Dec; 139(Pt A):15-26. PubMed ID: 26476132
[TBL] [Abstract][Full Text] [Related]
26. Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice.
Ma T; Du X; Pick JE; Sui G; Brownlee M; Klann E
J Neurosci; 2012 Oct; 32(40):13701-8. PubMed ID: 23035082
[TBL] [Abstract][Full Text] [Related]
27. Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice.
Gong Z; Huang J; Xu B; Ou Z; Zhang L; Lin X; Ye X; Kong X; Long D; Sun X; He X; Xu L; Li Q; Xuan A
J Neuroinflammation; 2019 Mar; 16(1):62. PubMed ID: 30871577
[TBL] [Abstract][Full Text] [Related]
28. Colivelin Ameliorates Impairments in Cognitive Behaviors and Synaptic Plasticity in APP/PS1 Transgenic Mice.
Wu M; Shi H; He Y; Yuan L; Qu X; Zhang J; Wang Z; Cai H; Qi J
J Alzheimers Dis; 2017; 59(3):1067-1078. PubMed ID: 28731445
[TBL] [Abstract][Full Text] [Related]
29. Hippocampal spatial memory impairments caused by the familial Alzheimer's disease-linked presenilin 1 M146V mutation.
Sun X; Beglopoulos V; Mattson MP; Shen J
Neurodegener Dis; 2005; 2(1):6-15. PubMed ID: 16908998
[TBL] [Abstract][Full Text] [Related]
30. Adiponectin Ameliorates Cognitive Behaviors and in vivo Synaptic Plasticity Impairments in 3xTg-AD Mice.
Yan XD; Qu XS; Yin J; Qiao J; Zhang J; Qi JS; Wu MN
J Alzheimers Dis; 2022; 85(1):343-357. PubMed ID: 34806605
[TBL] [Abstract][Full Text] [Related]
31. FFPM, a PDE4 inhibitor, reverses learning and memory deficits in APP/PS1 transgenic mice via cAMP/PKA/CREB signaling and anti-inflammatory effects.
Guo H; Cheng Y; Wang C; Wu J; Zou Z; Niu B; Yu H; Wang H; Xu J
Neuropharmacology; 2017 Apr; 116():260-269. PubMed ID: 28065587
[TBL] [Abstract][Full Text] [Related]
32. Synaptic modification by L-theanine, a natural constituent in green tea, rescues the impairment of hippocampal long-term potentiation and memory in AD mice.
Zhu G; Yang S; Xie Z; Wan X
Neuropharmacology; 2018 Aug; 138():331-340. PubMed ID: 29944861
[TBL] [Abstract][Full Text] [Related]
33. APP processing and synaptic plasticity in presenilin-1 conditional knockout mice.
Yu H; Saura CA; Choi SY; Sun LD; Yang X; Handler M; Kawarabayashi T; Younkin L; Fedeles B; Wilson MA; Younkin S; Kandel ER; Kirkwood A; Shen J
Neuron; 2001 Sep; 31(5):713-26. PubMed ID: 11567612
[TBL] [Abstract][Full Text] [Related]
34. Differences in Synaptic Dysfunction Between rTg4510 and APP/PS1 Mouse Models of Alzheimer's Disease.
Gelman S; Palma J; Tombaugh G; Ghavami A
J Alzheimers Dis; 2018; 61(1):195-208. PubMed ID: 29154272
[TBL] [Abstract][Full Text] [Related]
35. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice.
Shi Q; Chowdhury S; Ma R; Le KX; Hong S; Caldarone BJ; Stevens B; Lemere CA
Sci Transl Med; 2017 May; 9(392):. PubMed ID: 28566429
[TBL] [Abstract][Full Text] [Related]
36. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Nov; 86():241-58. PubMed ID: 25107586
[TBL] [Abstract][Full Text] [Related]
37. Viral gene transfer of APPsα rescues synaptic failure in an Alzheimer's disease mouse model.
Fol R; Braudeau J; Ludewig S; Abel T; Weyer SW; Roederer JP; Brod F; Audrain M; Bemelmans AP; Buchholz CJ; Korte M; Cartier N; Müller UC
Acta Neuropathol; 2016 Feb; 131(2):247-266. PubMed ID: 26538149
[TBL] [Abstract][Full Text] [Related]
38. D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model.
Faivre E; Hölscher C
J Alzheimers Dis; 2013; 35(2):267-83. PubMed ID: 23568101
[TBL] [Abstract][Full Text] [Related]
39. κ‑opioid receptor agonist, U50488H, inhibits pyroptosis through NLRP3 via the Ca
Song X; Cui Z; He J; Yang T; Sun X
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036389
[TBL] [Abstract][Full Text] [Related]
40. Increased hippocampal neurogenesis in the progressive stage of Alzheimer's disease phenotype in an APP/PS1 double transgenic mouse model.
Yu Y; He J; Zhang Y; Luo H; Zhu S; Yang Y; Zhao T; Wu J; Huang Y; Kong J; Tan Q; Li XM
Hippocampus; 2009 Dec; 19(12):1247-53. PubMed ID: 19309037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
